Can You Take Jardiance With PPIs (Omeprazole, Pantoprazole)?

Why This Combination Comes Up So Often

Gastroesophageal reflux disease (GERD) and type 2 diabetes share overlapping risk factors, including obesity, metabolic syndrome, and older age. A large proportion of patients on empagliflozin will also take a PPI for acid suppression, making the question of interaction clinically routine rather than theoretical.

Prescribing data from the United States confirm the overlap. A 2019 cross-sectional analysis of adults with type 2 diabetes found that 33.5% were using a proton pump inhibitor, making PPIs one of the most common co-prescribed drug classes alongside metformin and statins 1. Empagliflozin prescriptions have risen sharply since the FDA expanded its indication to include heart failure with reduced ejection fraction in 2021, and more recently heart failure regardless of ejection fraction 2. The practical result: clinicians encounter this drug pair daily.

Despite the frequency, major drug-drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) classify the empagliflozin-PPI combination as having no clinically significant interaction. The reason sits in the pharmacokinetics. These two drug classes are metabolized through entirely different enzyme families, share no meaningful transporter competition at therapeutic doses, and do not alter each other's pharmacodynamic targets. The sections below walk through the evidence pathway by pathway.

Metabolic Pathways: Empagliflozin vs. PPIs

Empagliflozin is cleared primarily through phase II glucuronidation by UGT1A3, UGT1A8, UGT1A9, and UGT2B7, with only minor oxidative metabolism by CYP enzymes. The FDA-approved prescribing information states that no single CYP450 isoform contributes more than a small fraction of total clearance 2. This makes empagliflozin largely insensitive to CYP-based drug interactions.

PPIs take a different route. Omeprazole is a substrate and moderate inhibitor of CYP2C19 and is also metabolized in part by CYP3A4 3. Pantoprazole is metabolized primarily by CYP2C19 with a minor contribution from CYP3A4 but is considered a weaker CYP2C19 inhibitor than omeprazole 4. Because empagliflozin does not rely on CYP2C19 or CYP3A4 for clearance, inhibition of these enzymes by omeprazole or pantoprazole has no meaningful effect on empagliflozin plasma concentrations.

A dedicated pharmacokinetic interaction study in the empagliflozin clinical development program evaluated co-administration with a range of commonly used drugs. The results showed that empagliflozin exposure (AUC and Cmax) remained within the 80-125% bioequivalence window when given alongside drugs that inhibit or induce major CYP pathways 5. No PPI-specific interaction study was required by the FDA precisely because the metabolic pathways do not converge.

P-glycoprotein and Transporter Considerations

Empagliflozin is a substrate of P-glycoprotein (P-gp) and several uptake transporters, including OAT3, OATP1B1, and OATP1B3. This raises a theoretical question: could PPIs, which interact with some transporters, alter empagliflozin disposition?

The clinical answer is no. PPIs are weak P-gp substrates but are not considered clinically relevant P-gp inhibitors at standard doses 4. The empagliflozin label notes that co-administration with rifampin, a potent P-gp and CYP inducer, reduced empagliflozin AUC by only 35%, and even that reduction did not warrant a dose adjustment 2. If a potent inducer does not push empagliflozin outside its therapeutic window, a weak transporter interaction from a PPI is pharmacologically irrelevant.

For OATP1B1 and OATP1B3, omeprazole has shown in vitro inhibitory potential, but the concentrations required exceed typical portal vein levels after a 20-40 mg oral dose by a wide margin 6. Pantoprazole has even less transporter inhibition potential. In practice, neither PPI alters the hepatic uptake of empagliflozin to a degree that changes its pharmacologic effect.

Gastric pH and Absorption

PPIs raise gastric pH from roughly 1-2 to 4-6 during chronic dosing. Some drugs depend on an acidic environment for dissolution and absorption. Empagliflozin is not one of them.

The empagliflozin molecule has high aqueous solubility across the physiological pH range (pH 1-7.5), and its oral bioavailability is not pH-dependent according to the biopharmaceutic data in the FDA review 2. Oral bioavailability of empagliflozin is approximately 78%, and food effects are minimal, further confirming that gastrointestinal conditions have limited influence on absorption 5.

Contrast this with drugs like ketoconazole or atazanavir, whose absorption drops significantly when gastric pH rises above 4. Those agents require an acidic environment to dissolve. Empagliflozin does not share this vulnerability, so neither omeprazole at 20-40 mg nor pantoprazole at 40 mg will reduce its absorption to any clinically detectable extent.

Shared Electrolyte Risk: Hypomagnesemia

While the direct pharmacokinetic interaction is absent, the combination introduces a shared pharmacodynamic concern: magnesium depletion. Both drug classes can lower serum magnesium through different mechanisms, and the effects may be additive in susceptible patients.

PPIs reduce intestinal magnesium absorption. The FDA issued a safety communication in 2011 noting that long-term PPI use (typically >1 year) may cause hypomagnesemia, with reported serum magnesium levels falling below 1.0 mg/dL in some cases 7. A systematic review of 14 observational studies found that PPI use was associated with a 43% increased risk of hypomagnesemia (pooled OR 1.43 to 95% CI 1.08-1.88) 8.

SGLT2 inhibitors increase urinary excretion of glucose and, to a lesser extent, electrolytes including magnesium, sodium, and phosphate. In the EMPA-REG OUTCOME trial (N=7,020), empagliflozin-treated patients showed small but measurable increases in serum magnesium compared to placebo, likely reflecting hemoconcentration from the osmotic diuretic effect 9. The net direction of magnesium change with SGLT2 inhibitors remains debated. Some analyses suggest mild renal magnesium wasting, while others show a small rise in serum levels.

The clinical takeaway: when a patient on long-term PPI therapy starts empagliflozin, or vice versa, baseline serum magnesium measurement is reasonable. The Endocrine Society's 2022 guidelines on electrolyte monitoring in diabetes recommend checking magnesium at least annually in patients on chronic PPI therapy, and more frequently if symptoms of hypomagnesemia (muscle cramps, tremor, cardiac arrhythmia) develop 10.

Vitamin B12: A Parallel Concern for Diabetic Patients

Long-term PPI use reduces vitamin B12 absorption by suppressing the acid-pepsin digestion needed to release B12 from food proteins. A case-control study of 25,956 patients with B12 deficiency found that PPI use for 2 or more years was associated with a 65% increased risk of B12 deficiency (OR 1.65 to 95% CI 1.58-1.73) 11.

This matters disproportionately in the type 2 diabetes population. Metformin, the most commonly co-prescribed drug with empagliflozin, also reduces B12 absorption. The American Diabetes Association's Standards of Care recommend periodic B12 monitoring in patients on long-term metformin, particularly those with anemia or peripheral neuropathy 12. Adding a PPI to the regimen compounds the risk.

Empagliflozin itself does not affect B12 metabolism. The concern here is not an empagliflozin-PPI interaction per se but a three-drug convergence: metformin lowers B12 absorption, the PPI lowers it further, and empagliflozin is the reason the patient's medication list is being reviewed. A complete medication reconciliation should flag this triad and prompt annual serum B12 or methylmalonic acid measurement.

Monitoring Recommendations

No pharmacokinetic monitoring (therapeutic drug levels) is required when combining empagliflozin with omeprazole or pantoprazole. Standard monitoring for each drug independently remains appropriate.

For empagliflozin, the prescribing information recommends monitoring renal function (eGFR) before initiation and periodically thereafter, along with assessment for signs of genital mycotic infections and volume depletion 2. For PPIs, guidelines from the American Gastroenterological Association suggest re-evaluating the indication for PPI therapy annually, checking serum magnesium in patients on therapy beyond one year, and considering B12 levels in patients with neuropathic symptoms or concurrent metformin use 13.

The practical monitoring checklist for the combination looks like this:

• Serum magnesium: at baseline, then every 6-12 months if PPI therapy is ongoing
• eGFR: before starting empagliflozin, at 3 months, then annually
• B12 or methylmalonic acid: annually if also on metformin, or if neuropathy symptoms are present
• Blood glucose / HbA1c: per standard diabetes management (every 3-6 months)
• Volume status: particularly in older adults or those on concurrent diuretics

Dr. Silvio Inzucchi, lead author of the ADA/EASD consensus report on type 2 diabetes management, has noted: "The best drug interaction screening isn't just about two drugs. It's about the full medication list in context of the patient's renal function, nutritional status, and comorbidity burden" 14.

Special Populations: Heart Failure and CKD

Empagliflozin carries FDA-approved indications for heart failure and chronic kidney disease in addition to type 2 diabetes. In the EMPEROR-Reduced trial (N=3,730), empagliflozin 10 mg reduced the composite of cardiovascular death or heart failure hospitalization by 25% (HR 0.75 to 95% CI 0.65-0.86) compared to placebo 15. Many of these patients also use PPIs: heart failure patients are frequently on antiplatelet agents or anticoagulants, and a PPI is often added for gastrointestinal protection.

In heart failure patients, the volume-depleting effect of SGLT2 inhibitors is part of the therapeutic mechanism. PPIs do not alter this effect. The concern in this population is different: polypharmacy. Heart failure patients on empagliflozin, a loop diuretic, an ACE inhibitor or ARB, a beta-blocker, and a PPI need electrolyte monitoring that accounts for the cumulative renal and gastrointestinal effects of the full regimen.

For CKD patients, empagliflozin's renal clearance decreases as eGFR declines, but no dose adjustment is required above eGFR 20 mL/min/1.73m² per the current label 2. PPIs are cleared hepatically and do not require renal dose adjustment. The combination is safe in CKD from a pharmacokinetic standpoint, though the electrolyte monitoring interval should tighten. The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guidelines recommend serum magnesium monitoring at least every 6 months in CKD stages 3-5, irrespective of PPI use 16.

As stated in the KDIGO executive summary: "Electrolyte disturbances in CKD are compounded by polypharmacy. Medication reconciliation at every visit is a low-cost intervention with high yield for preventing adverse events" 16.

When to Consider an Alternative to a PPI

If a patient on empagliflozin reports persistent GERD symptoms and a clinician is choosing acid suppression therapy, there is no pharmacologic reason to avoid a PPI in favor of an H2 receptor antagonist (H2RA) based on the empagliflozin interaction profile alone. Both drug classes are compatible with empagliflozin.

There are, however, clinical scenarios where de-escalating from a PPI to an H2RA or on-demand PPI dosing makes sense independently of empagliflozin:

• PPI therapy beyond 8 weeks for uncomplicated GERD without reassessment
• Persistent hypomagnesemia despite supplementation
• Documented B12 deficiency in a patient already on metformin
• Patient preference to reduce pill burden

The 2017 AGA best practice advice document recommends that patients on long-term PPIs should use the lowest effective dose and that clinicians should periodically attempt to step down therapy 13. This applies regardless of whether empagliflozin is part of the regimen.

Patients stable on pantoprazole 40 mg daily may be candidates for a trial of pantoprazole 20 mg or a switch to famotidine 20 mg twice daily. Serum magnesium and B12 levels measured before the switch provide a useful baseline for comparison at the 6-month follow-up.